Back to News
Market Impact: 0.35
Prelude Therapeutics Receives FDA Clearance For PRT13722 IND In HR+/HER2-Breast Cancer
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Prelude Therapeutics announced that the FDA cleared the investigational new drug (IND) application for PRT13722, allowing the precision-oncology company to advance the program into clinical development. The regulatory clearance is a meaningful pipeline catalyst, though the article provides no efficacy, safety, trial-design, or financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
PRLD0.80
More News
- Biotech stocks are surging. How investors can play the new drug innovation boom
- Ukraine says Starlink and Starshield high speed restrictions have been lifted
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- How This County Made the Data Center Boom Pay Off
- J&J prostate cancer drug shows promising tumor responses in early trial
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine